Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02545504 · ClinicalTrials.gov registry record · Phase 3
Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 432
- Enrollment target
NCT02545504 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 432 participants.
The verdict
NCT02545504, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 432 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the efficacy of andecaliximab (GS-5745) versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.
Interventions
- DRUG Placebo
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG 5-fluorouracil
- DRUG Andecaliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2015-10-13 |
| Est. Completion | 2019-05-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02545504
The ClinicalTrials.gov registry entry for NCT02545504 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02545504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02545504 about?
NCT02545504 is a clinical study titled "Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma". The primary objective of this study is to compare the efficacy of andecaliximab (GS-5745) versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.
What is the current status of trial NCT02545504?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 432 participants. The study started on 2015-10-13. Estimated completion is 2019-05-15.
What interventions are being tested in trial NCT02545504?
The interventions under investigation include: Placebo (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), 5-fluorouracil (DRUG), Andecaliximab (DRUG).
Who is sponsoring clinical trial NCT02545504?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.